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Tau is a structural microtubule-associated
protein (MAP) that is widely expressed in
the mammalian nervous system. It stabi-
lizes neuronal microtubules, facilitating
their roles in the establishment of cell
polarity, neurite outgrowth, and axonal
transport (Wang and Mandelkow, 2015).
Prominent accumulations of fibrillar
aggregates of hyperphosphorylated tau in
the CNS are pathological hallmarks for a
broad group of neurodegenerative dis-
eases called “tauopathies” (Ballatore et al.,
2007).
The human tau gene undergoes alterna-
tive splicing to produce six isoforms. Alter-
native splicing of tau exon 10 generates tau
proteins that contain either three (3R) or
four (4R) microtubule binding repeats. In
the adult human brain, the 3R and 4R tau
isoforms are expressed at a 1:1 ratio. This
delicate balance of 3R and 4R tau appears to
be critical for neuronal function because
deviations from this ratio are characteristic
of several tauopathies. For example, tau
mutations associated with frontotemporal
dementia with parkinsonism linked to
chromosome 17 (FTDP-17) disrupt only
exon 10 splicing without altering the pri-
mary sequence of tau (Wang and Man-
delkow, 2015). However, the functional
differences between 3R and 4R tau and the
precise mechanism by which imbalances of
tau isoforms contribute to diseases remain
largely elusive.
In a recent publication in The Journal
of Neuroscience, Lacovich et al. (2017)
extended our understanding of the rela-
tionship between the imbalances of tau
isoforms and axonal transport of amyloid
precursor protein (APP) by means of live-
cell imaging in human-derived neurons.
This is important because APP is the pre-
cursor protein of A, which plays a central
role in Alzheimer’s disease (AD) pathol-
ogy. The authors first altered the relative
ratio of endogenous 3R and 4R tau in neu-
ronal cultures differentiated from human
embryonic stem cells by means of a trans-
splicing RNA reprogramming strategy
that drives the inclusion or exclusion of
exon 10 in the endogenous tau transcript.
Lacovich et al. (2017) next evaluated the
effects of perturbations of the ratio of tau
isoforms on neuronal survival and mor-
phology. They analyzed neuronal structure
and polarization in transduced neurons by
immunostaining against APP and Tau,
which are makers for membrane and cyto-
skeletal structures. The authors did not ob-
serve significant differences in the number
of neurons that expressed Tau and APP, the
length of axons and dendrites, the number
of axonal swellings, or accumulation of tau
in transduced neurons compared with con-
trols. Furthermore, the shift in the balance
of tau isoforms did not alter the total
amount of tau protein or tau phosphoryla-
tion. Together, these results indicate that the
use of the trans-splicing strategy of Lacovich
et al. (2017) successfully modulated the rel-
ative ratio of 3R and 4R tau isoforms in hu-
man-derived neurons without altering tau
protein expression and the phosphorylation
state or neuronal survival, polarization, and
morphology. This provides a useful human
cellular model for investigating the effects of
an imbalance of human tau isoforms on
early neuronal dysfunction.
A large body of in vitro and in vivo data
suggests that tau mutations disrupt axonal
transport. For example, overexpression of
wild-type 4R tau impedes vesicle and organ-
elle trafficking by disrupting the interaction
between microtubules and motor proteins
(Seitz et al., 2002; Stamer et al., 2002).
Transgenic mice that express missense hu-
man mutations in exon 10 of tau (P301S or
P301L) also have deficits in axonal transport
(Ittner et al., 2008; Bull et al., 2012; Gilley et
al., 2012; Rodríguez-Martín et al., 2016).
Furthermore, overexpression of 3R tau dis-
rupts axonal transport and synaptic func-
tion in Drosophila motor neurons (Chee et
al., 2005), and the expression of either wild-
type or mutant 4R tau causes axonal degen-
eration in Caenorhabditis elegans (Kraemer
et al., 2003). To understand how tau dys-
function influences the generation of A in
AD, Lacovich et al. (2017) assessed the ef-
fects of imbalance in tau isoforms on axonal
transport of fluorescently tagged APP in hu-
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man-derived neurons, using live-cell imag-
ing. Increased levels of either 3R or 4R tau
isoforms led to significant reductions in the
average velocities and the number of mov-
ing APP-carrying vesicles in both antero-
grade and retrograde directions. These
results indicated that changes in the ratio of
tau isoforms have an effect on the regulation
of axonal transport of APP.
To investigate how tau-isoform imbal-
ance affects transport of APP in greater
depth, the authors quantified the run
length, the number of pauses per trajectory,
reversion of directionality, and segmental
velocity distributions. Shifting the balance
to 3R tau isoforms favored the anterograde
movement of APP vesicles, with a signifi-
cant increase in anterograde run lengths and
a reduction in retrograde run lengths. In
contrast, shifting the balance to 4R tau iso-
forms promoted a retrograde bias by means
of a significant reduction in anterograde
velocity.
These findings imply an intriguing link
between the endogenous ratio of tau iso-
forms and APP trafficking. Increases in ei-
ther 3R tau or 4R tau increase anterograde
and retrograde transport, respectively. This
is important because, as discussed below,
disrupting APP transport could affect its
processing and thus the generation of A.
APP is a trans-membrane protein that is
processed by three secretases. In the amy-
loidogenic pathway, APP is first cleaved by
-secretase (BACE1) to produce soluble
APP and a C-terminal fragment (CTF).
Subsequent cleavage ofCTF by-secretase
yields A peptide, which aggregates in ex-
tracellular amyloid plaques in AD patients.
Although the molecular mechanisms sur-
rounding APP processing have been exten-
sively studied, substantial controversy
remains over where cleavage occurs and
where A is released.
According to one model, APP is deliv-
ered to presynaptic terminals by fast antero-
grade transport. APP can interact directly or
indirectly with the kinesin light chain
subunit of the kinesin-1 transport machin-
ery (Scheinfeld et al., 2002). The observation
that - and -secretases are contained
within the same transport vesicle as APP led
to the suggestion that A cleavage occurs in
transit (Kamal et al., 2001). According to
this hypothesis, the inhibition of antero-
grade transport of APP by increasing 4R tau
could increase dwell time of APP vesicles in
transit, which would result in the premature
proteolysis of APP and generation of
cleavage products, including A. The find-
ing that kinesin light chain-deficient ani-
mals, when crossed with APP transgenic
mice, displayed axonal pathology, increased
amyloid levels and deposits in brain is con-
sistent with this model (Stokin et al., 2005).
Another model proposes that synapses
are sites of A release and toxicity. A signif-
icant proportion of full-length APP and its
C-terminal cleavage products accumulated
at presynaptic terminals (Buxbaum et al.,
1998).CTFs, which are generated from ax-
onally transported APP, are cleaved to A
peptides that are subsequently released and
deposited in the axon terminals (Lazarov et
al., 2002). According to this model, in-
creases in the anterograde transport of APP
by elevating 3R tau could lead to an accu-
mulation of APP at distal axons, and thus an
increase in the generation and release of A
at synapses.
Finally, several studies have indicated
that nascent APP and BACE1 mature while
being trafficked along the constitutive secre-
tory pathway from the ER to the plasma
membrane. Unlike many cell surface recep-
tors, most APP is rapidly internalized into
early endosomes containing BACE1 and
-secretase. Indeed, endosomal compart-
ments are acidic, which is optimal for
BACE1 activity, and some work indicates
that BACE1 interacts with APP predomi-
nantly in endosomes under native condi-
tions (Kinoshita et al., 2003). Vesicles
containing A are either recycled to the sur-
face, dumping A into the extracellular
space, or they fuse with lysosomes, where
A is degraded (O’Brien and Wong, 2011).
In support of this model, A levels are in-
creased by promoting APP or BACE1 inter-
nalization, whereas blocking internalization
reduces Aproduction. If this model is cor-
rect, impairment of APP anterograde trans-
port relative to retrograde transport by the
elevation of 4R tau could reduce the amount
of APP being trafficked to the surface and
get internalized for processing, thus leading
to a reduction in amyloidogenesis. On the
other hand, inhibition of APP retrograde
transport relative to anterograde transport
by the elevation of 3R tau could result in an
accumulation of APP in endosomes as they
failed to traffic back to the cell soma and fuse
to lysosomes for degradation. Reductions in
lysosomal degradation could increase the
amount of Abeing secreted extracellularly.
The findings by Lacovich et al. (2017) thus
provide an important link between tau dys-
function and abnormal endocytic response
in AD.
In conclusion, many mouse models of
tauopathies have been generated to explore
the mechanism of tau dysfunction in
neurodegenerative disorders, and many of
these models accurately model key aspects
of human disorders (Noble et al., 2010).
However, the critical differences between
the mouse and human genome may make it
difficult to analyze the role of tau isoform
balance because humans express a mixture
of 3R and 4R tau, whereas adult mice
express only 4R tau (Takuma et al., 2003).
Moreover, most mouse models of tauopa-
thies are transgenic lines that overexpress
wild-type tau isoforms or tau isoforms with
disease-associated mutations. This raises the
possibility that tau expression at nonphysi-
ological levels in such models might itself
influence pathogenesis in ways that differ
from tau dysfunction in humans, even if
the endpoints are similar (Gilley et al.,
2011). Lacovich et al. (2017) addressed these
issues using a novel trans-splicing RNA re-
programming approach in human-derived
neurons. They have created a useful human
cellular model to dissect the functional con-
sequences of human tau isoform imbalance
without altering total tau protein or impair-
ing other tau-dependent functions. Fur-
thermore, their findings that changes in the
endogenous 3R:4R tau ratio significantly
disrupt the axonal transport of APP in hu-
man neurons significantly advance our un-
derstanding of the possible pathological
links between tau isoform imbalances and
APP metabolism. Their data raise new per-
spectives on the modulation of abnormal
tau metabolism as a potential therapeutic
intervention for human tauopathies, such
as AD.
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